產品櫥窗
-
EIDD-2801, >98%
產品型號:101-2349386-89-4 商品規格: |
|
EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.
C13H19N3O7
M.W.: 329.31
M.W.: 329.31
EIDD-2801 is an orally bioavailable NHC-prodrug. NHC is potently antiviral against SARS-CoV-2, MERS-CoV and SARS-CoV in primary human epithelial cell cultures without cytotoxicity. NHC is effective against remdesivir (RDV)-resistant vi-rus and multiple distinct zoonotic CoV. NHC antiviral activity is associated with increased viral mutation rates.
EIDD-2801 is efficiently hydrolyzed in vivo after absorption, resulting in detection of only free NHC in plasma. Therapeutic EIDD-2801 is potently antiviral against SARS-CoV in vivo but the degree of clinical benefit is dependent on the time of initiation post-infection. EIDD-2801 robustly reduces MERS-CoV infectious titers, viral RNA, and pathogenesis under both prophylactic and early therapeutic conditions
Sheahan TP, et al. Sci Transl Med. 2020 Apr 29;12(541).
Toots M, et al. Sci Transl Med. 2019 Oct 23;11(515).
Sheahan TP, et al. Sci Transl Med. 2020 Apr 29;12(541).
Toots M, et al. Sci Transl Med. 2019 Oct 23;11(515).
Store at -20℃
Shipping at Room Temp within Taiwan; may vary elsewhere
Shipping at Room Temp within Taiwan; may vary elsewhere